NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a late-stage biopharmaceutical company focused on developing oral, non-statin medicines for cardiovascular disease patients with elevated LDL-C, has announced the grant of inducement share options to a new non-executive hire. The Compensation Committee approved options for 59,200 ordinary shares under the 2024 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $17.25 per share, matching the closing market price on August 1, 2024. The shares will vest over four years, with 25% vesting after one year and the remainder vesting in 36 monthly installments, subject to continued employment. This grant is part of NewAmsterdam's strategy to attract and retain key talent in its mission to develop innovative cardiovascular treatments.
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), un'azienda biofarmaceutica in fase avanzata focalizzata nello sviluppo di farmaci orali non statinici per pazienti con malattie cardiovascolari e livelli elevati di LDL-C, ha annunciato l'assegnazione di opzioni azionarie di indennizzo a una nuova assunzione non esecutiva. Il Comitato Compensazioni ha approvato opzioni per 59.200 azioni ordinarie nell'ambito del Piano di Indennizzo 2024, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Le opzioni hanno un prezzo di esercizio di $17.25 per azione, corrispondente al prezzo di chiusura del mercato del 1 agosto 2024. Le azioni si matureranno in quattro anni, con il 25% che matura dopo un anno e il restante che matura in 36 rate mensili, soggetto a un impiego continuativo. Questo conferimento è parte della strategia di NewAmsterdam per attrarre e trattenere talenti chiave nella sua missione di sviluppare trattamenti cardiovascolari innovativi.
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), una empresa biofarmacéutica en etapa tardía centrada en desarrollar tratamientos orales no estatínicos para pacientes con enfermedades cardiovasculares y niveles elevados de LDL-C, ha anunciado la concesión de opciones de acciones por incentivo a una nueva contratación no ejecutiva. El Comité de Compensación aprobó opciones por 59,200 acciones ordinarias bajo el Plan de Incentivo 2024, en cumplimiento con la Regla de Cotización Nasdaq 5635(c)(4).
Las opciones tienen un precio de ejercicio de $17.25 por acción, coincidiendo con el precio de cierre del mercado el 1 de agosto de 2024. Las acciones se adquirirán durante cuatro años, con un 25% adquiriéndose después de un año y el resto adquiriéndose en 36 cuotas mensuales, sujeto a un empleo continuado. Esta concesión es parte de la estrategia de NewAmsterdam para atraer y retener talento clave en su misión de desarrollar tratamientos cardiovasculares innovadores.
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), 심혈관 질환 환자를 위한 경구 비 스타틴 약물 개발에 초점을 맞춘 후기 단계의 생명공학 회사는 새로운 비상임 직원을 위해 유인 주식 옵션을 부여한다고 발표했습니다. 보상 위원회는 Nasdaq 상장 규칙 5635(c)(4)에 따라 2024 유인 계획 하에 59,200주의 옵션을 승인했습니다.
이 옵션의 행사 가격은 주당 $17.25로, 2024년 8월 1일의 시장 종가와 일치합니다. 주식은 4년에 걸쳐 발생하며, 1년 후에 25%가 발생하고 나머지는 36개월에 걸쳐 매달 발생합니다. 이는 지속적인 재직을 조건으로 합니다. 이 부여는 혁신적인 심혈관 치료제를 개발하기 위한 NewAmsterdam의 주요 인재 유치 및 유지 전략의 일환입니다.
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), une entreprise biopharmaceutique en phase avancée se concentrant sur le développement de médicaments oraux non statiniques pour les patients atteints de maladies cardiovasculaires avec un LDL-C élevé, a annoncé l'octroi d'options d'achat d'actions d'incitation à une nouvelle embauche non exécutive. Le Comité de Rémunération a approuvé des options pour 59 200 actions ordinaires dans le cadre du Plan d'Incitation 2024, conformément à la Règle de Cotation Nasdaq 5635(c)(4).
Les options ont un prix d'exercice de 17,25 $ par action, correspondant au prix de clôture du marché du 1er août 2024. Les actions se débloqueront sur quatre ans, avec 25 % se débloquant après un an et le reste se débloquant en 36 versements mensuels, sous réserve d'un emploi continu. Cet octroi fait partie de la stratégie de NewAmsterdam visant à attirer et retenir des talents clés dans sa mission de développer des traitements cardiovasculaires innovants.
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), ein biopharmazeutisches Unternehmen in der späten Phase, das sich auf die Entwicklung oraler, nicht-statinhaltiger Medikamente für Patienten mit Herz-Kreislauf-Erkrankungen und erhöhtem LDL-C konzentriert, hat die Gewährung von Incentive-Aktienoptionen an eine neue nicht-executive Einstellung bekannt gegeben. Der Vergütungsausschuss genehmigte Optionen für 59.200 Stammaktien im Rahmen des Incentive-Plans 2024, gemäß der Nasdaq-Listing-Regel 5635(c)(4).
Die Optionen haben einen Ausübungspreis von $17.25 pro Aktie, was dem Schlusskurs vom 1. August 2024 entspricht. Die Aktien werden über vier Jahre fällig, wobei 25 % nach einem Jahr fällig werden und der Rest in 36 monatlichen Raten fällig wird, vorbehaltlich einer kontinuierlichen Anstellung. Diese Gewährung ist Teil der Strategie von NewAmsterdam, Schlüsselpersonen anzuwerben und zu halten, um innovative kardiovaskuläre Behandlungen zu entwickeln.
- Attracting new talent with stock options aligns employee interests with company goals
- Compliance with Nasdaq listing rules demonstrates good corporate governance
- Potential dilution of existing shareholders' equity due to new share options
NAARDEN, The Netherlands and MIAMI, Aug. 02, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 59,200 of NewAmsterdam’s ordinary shares to one non-executive new hire. The share options were granted as an inducement material to the employee’s acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price per share equal to
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
FAQ
How many inducement share options did NewAmsterdam Pharma (NAMS) grant on August 1, 2024?
What is the exercise price of the share options granted by NewAmsterdam Pharma (NAMS)?
What is the vesting schedule for the inducement share options granted by NewAmsterdam Pharma (NAMS)?
Under which plan were the inducement share options granted by NewAmsterdam Pharma (NAMS)?
